Brought to you by 
Pharmaxis grants BI option on NASH program PXS4728A; option exercised
16 Mar 2021
Executive Summary
For a fee of €1.25mm ($1.33mm), Pharmaxis Ltd. granted Boehringer Ingelheim GMBH an option to license exclusive worldwide rights to its Phase I nonalcoholic steatohepatitis (NASH) candidate PXS4728A, an inhibitor of semicarbazide-sensitive amine oxidase (SSAO; also known as vascular adhesion protein-1 (VAP-1)).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pharmaxis grants BI option on NASH program PXS4728A; option exercised
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice